



SUPPLEMENTARY MATERIAL TO  
**Synthesis, spectroscopic characterization and pharmacological  
evaluation of oxazolone derivatives**

GHULAM FAREED<sup>1,2\*</sup>, NIGHAT AFZA<sup>1</sup>, MUHAMMAD ALI VERSIANI<sup>2</sup>,  
NAZIA FAREED<sup>2</sup>, UZMA RASHEED MUGHAL<sup>3</sup>, MAHBOOB ALI KALHORO<sup>1</sup>,  
LUBNA IQBAL<sup>1</sup> and MEHREEN LATEEF<sup>1</sup>

<sup>1</sup>Pharmaceutical Research Center, PCSIR Laboratories Complex Karachi, Shahrah-e-Dr. Salim-uz-Zaman Siddiqui Karachi-75280, Sindh, Pakistan, <sup>2</sup>Department of Chemistry, Federal Urdu University of Arts, Science and Technology, Ghulshan-e-Iqbal, Karachi-75300, Sindh, Pakistan and <sup>3</sup>HEJ Research Institute of Chemistry, ICCBS, University of Karachi, Karachi-75280, Pakistan

J. Serb. Chem. Soc. 78 (8) (2013) 1127–1134

ANALYTIC AND SPECTRAL DATA FOR THE SYNTHESIZED COMPOUNDS

4-[(Z)-(4-Chloro-3-nitrophenyl)methylidene]-2-phenyl-5(4H)-oxazolone (2).  
*R*<sub>f</sub>: 0.67 (ethyl acetate: hexane, 2:8); Anal. Calcd. for C<sub>16</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>4</sub>: C, 58.46; H, 2.76; N, 8.52 %. Found: C, 58.41; H, 2.77; N, 8.50 %; IR (KBr, cm<sup>-1</sup>): 1799, 1659, 1536, 1451, 1324, 1172, 868, 644; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 7.13 (1H, *s*, 6-H), 7.52–7.68 (5H, *m*, Ar-H), 8.15–8.18 (2H, *m*, Ar-H), 8.80 (1H, *s*, Ar-H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 166.70, 164.98, 146.80, 136.57, 135.84, 132.77, 132.03, 129.36, 129.16, 128.68, 127.88, 126.23, 125.60, 125.49; EI-MS (*m/z* (relative abundance, %)): 330 (M+2, 12.3), 328 (M<sup>+</sup>, 37.5), 105 (100), 77 (71.6), 44 (93.1).

4-[(Z,E)-3-(4-Methoxyphenyl)-2-propenylidene]-2-phenyl-5(4H)-oxazolone (3). *R*<sub>f</sub>: 0.70 (ethyl acetate: hexane, 2:8); Anal. Calcd. for C<sub>19</sub>H<sub>15</sub>NO<sub>3</sub>: C, 74.74; H, 4.95; N, 4.59 %. Found: C, 74.70; H, 4.97; N, 4.57 %; IR (KBr, cm<sup>-1</sup>): 1781, 1652, 1593, 1328, 1256, 1161, 865; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 3.84 (3H, *s*, OCH<sub>3</sub>), 7.38 (1H, *d*, *J* = 14.5 Hz, CH–CH=CH), 7.42 (1H, *d*, *J* = 9.8 Hz, CH–CH=CH), 6.95 (1H, *dd*, *J* = 9.8, 14.5 Hz, CH–CH=CH), 7.45–7.58 (5H, *m*, Ar-H), 7.92–8.12 (4H, *m*, Ar-H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 166.03, 162.37, 159.32, 135.13, 134.20, 132.51, 132.03, 129.45, 129.42, 129.36, 129.16, 128.71, 127.81, 114.57, 14.02; EI-MS (*m/z* (relative abundance, %)): 305 (M<sup>+</sup>, 39.2), 277 (3.0), 105 (100), 77 (29.4), 44 (68.3).

\* Corresponding author. E-mail: fareedchm@yahoo.com

4-[(Z)-(4-Chloro-3-nitrophenyl)methylidene]-2-methyl-5(4H)-oxazolone (**4**). *R<sub>f</sub>*: 0.77 (ethyl acetate:hexane, 2:8); Anal. Calcd. for C<sub>11</sub>H<sub>7</sub>ClN<sub>2</sub>O<sub>4</sub>: C, 49.55; H, 2.65; N, 10.51 %. Found: C, 49.57; H, 2.61; N, 10.53 %; IR (KBr, cm<sup>-1</sup>): 3072, 1805, 1661, 1607, 1533, 1360, 1261, 1168, 890, 657, 629; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 2.42 (3H, *s*, CH<sub>3</sub>), 7.24 (1H, *s*, 6-H), 7.57–8.10 (2H, *m*, Ar-H), 8.70 (1H, *s*, Ar-H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 168.38, 160.19, 146.88, 136.57, 132.77, 129.90, 128.61, 125.64, 125.41, 125.01, 11.12; EI-MS (*m/z* (relative abundance, %)): 268 (M<sup>+2</sup>, 59.4), 266 (M<sup>+</sup>, 29), 105 (3.9), 114 (64.5) 77 (35), 44 (100).

4-[(Z)-(3,5-Dibromo-4-hydroxyphenyl)methylidene]-2-methyl-5(4H)-oxazolone (**5**). *R<sub>f</sub>*: 0.65 (ethyl acetate:hexane, 2:8); Anal. Calcd. for C<sub>11</sub>H<sub>7</sub>Br<sub>2</sub>NO<sub>3</sub>: C, 36.60; H, 1.95; N, 3.88 %. Found: C, 36.62; H, 1.94; N, 3.85 %; IR (KBr, cm<sup>-1</sup>): 3071, 1760, 1670, 1580, 1479, 1302, 1139, 876, 646; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 2.14 (3H, *s*, CH<sub>3</sub>), 7.24 (1H, *s*, 6-H), 7.97 (2H, *s*, Ar-H), 9.88 (1H, *s*, OH); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 168.38, 160.19, 151.51, 131.35, 129.02, 126.27, 125.52, 113.41, 14.03; EI-MS (*m/z* (relative abundance, %)): 364 (M+4, 10), 362 (M+2, 12), 360 (M<sup>+</sup>, 39), 105 (100), 77 (12), 44 (91.8).

4-[(Z)-(3,5-Dibromo-4-hydroxyphenyl)methylidene]-2-phenyl-5(4H)-oxazolone (**6**). *R<sub>f</sub>*: 0.72 (ethyl acetate:hexane, 2:8); Anal. Calcd. for C<sub>16</sub>H<sub>9</sub>Br<sub>2</sub>NO<sub>3</sub>: C, 45.42; H, 2.14; N, 3.31 %. Found: C, 45.40; H, 2.15; N, 3.32 %; IR (KBr, cm<sup>-1</sup>): 3075, 1650, 1541, 1416, 1241, 652, 644; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 7.26 (1H, *s*, 6-H), 7.97 (2H, *s*, Ar-H), 7.24–8.32 (5H, *m*, Ar-H) 9.88 (1H, *s*, OH); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 166.70, 164.91, 151.51, 134.96, 132.01, 131.31, 129.10, 127.88, 127.11, 126.27, 113.44; EI-MS (*m/z* (relative abundance, %)): 427 (M+4, 2), 425 (M+2, 3), 423 (M<sup>+</sup>, 2.5), 105 (100), 77 (76.8), 44 (73.5).

4-[(Z)-(2-Ethoxyphenyl)methylidene]-2-phenyl-5(4H)-oxazolone (**7**). *R<sub>f</sub>*: 0.72 (ethyl acetate: hexane, 2:8); Anal. Calcd. for C<sub>18</sub>H<sub>15</sub>NO<sub>3</sub>: C, 73.71; H, 5.15; N, 4.78 %. Found: C, 73.70; H, 5.17; N, 4.77 %; IR (KBr, cm<sup>-1</sup>): 1788, 1768, 1664, 1595, 1557, 1488, 1447, 1248, 1168, 1045; <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>, δ / ppm): 1.50 (3H, *t*, *J* = 6.5 Hz, CH<sub>3</sub>CH<sub>2</sub>O), 4.15 (2H, *q*, *J* = 6.5 Hz, CH<sub>3</sub>CH<sub>2</sub>O), 6.88–7.08 (5H, *m*, Ar-H), 7.24 (1H, *s*, 6-H), 7.35–8.87 (4H, *m*, Ar-H); <sup>13</sup>C-NMR (75 MHz, CDCl<sub>3</sub>, δ / ppm): 166.70, 164.98, 157.80, 132.03, 130.96, 129.92, 129.36, 129.16, 128.74, 127.88, 127.69, 122.04, 121.31, 117.24, 64.52, 13.83; EI-MS (*m/z* (relative abundance, %)): 293 (M<sup>+</sup>, 38.1), 265 (3.7), 105 (100), 77 (77.2).